Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With a Major Depressive Episode Associated With Bipolar II Disorder

Next Previous
Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With a Major Depressive Episode Associated With Bipolar II Disorder

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Navacaprant (Primary)
  • Indications Bipolar II disorders
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Neumora Therapeutics

Most Recent Events

  • 03 Mar 2025 According to a Neumora Therapeutics media release, the company announced that it has discontinued the Phase 2 clinical trial investigating navacaprant for the treatment of bipolar depression to prioritize the resources allocated to navacaprant on the KOASTAL program.
  • 03 Mar 2025 Status changed from recruiting to discontinued according to a Neumora Therapeutics media release.
  • 14 Aug 2024 According to a Neumora Therapeutics media release, Company will host a roundtable discussion on the neuropsychiatric treatment landscape and role of kappa opioid receptor antagonists (KORAs) in neuropsychiatry. The discussion will feature leading experts in neuropsychiatry and will take place on Thursday, September 12 at 8:00 a.m. ET.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top